Tumour immune escape via P2X7 receptor signalling

Ricardo M. Sainz, Jorge Humberto Rodriguez-Quintero, Maria Constanza Maldifassi, Brendon M. Stiles, Erik Wennerberg

Research output: Contribution to journalShort surveypeer-review

Abstract

While P2X7 receptor expression on tumour cells has been characterized as a promotor of cancer growth and metastasis, its expression by the host immune system is central for orchestration of both innate and adaptive immune responses against cancer. The role of P2X7R in anti-tumour immunity is complex and preclinical studies have described opposing roles of the P2X7R in regulating immune responses against tumours. Therefore, few P2X7R modulators have reached clinical testing in cancer patients. Here, we review the prognostic value of P2X7R in cancer, how P2X7R have been targeted to date in tumour models, and we discuss four aspects of how tumours skew immune responses to promote immune escape via the P2X7R; non-pore functional P2X7Rs, mono-ADP-ribosyltransferases, ectonucleotidases, and immunoregulatory cells. Lastly, we discuss alternative approaches to offset tumour immune escape via P2X7R to enhance immunotherapeutic strategies in cancer patients.

Original languageEnglish (US)
Article number1287310
JournalFrontiers in immunology
Volume14
DOIs
StatePublished - 2023

Keywords

  • ART1
  • CD38
  • CD39
  • P2X7 receptor
  • cancer immunotherapy
  • tumour immune escape
  • tumour microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Tumour immune escape via P2X7 receptor signalling'. Together they form a unique fingerprint.

Cite this